Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06948591

BioBrace® Augmentation in Anterior Cruciate Ligament Reconstruction Procedures

This research study will evaluate mid-term clinical safety and performance outcomes of the BioBrace® Reinforced Implant when used to augment a tissue graft during anterior cruciate ligament (ACL) reconstruction.

Recruiting

Interested in participating?

Request Info

Key information

Age range

14 year–70 year

Sex eligibility

All sexes

Study type

Observational

Primary location

ConMed

New Haven, Connecticut, 06513, United States

Location status: Recruiting

Location contact

About this study

This is a multi-center, single arm, open label registry investigating anterior cruciate ligament reconstruction (ACLR) procedures where the tissue graft is augmented with BioBrace®. Subjects meeting the inclusion/exclusion criteria will be enrolled retrospectively or prospectively. Clinical evaluations will be conducted at baseline (pre-operatively) and at 6 months, 1-, 2-, and 3-years post-operatively using various patient-reported outcome measures to assess pain, function, return to activity, and safety post-surgery.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Underwent ACL reconstruction with a tissue graft augmented with BioBrace® within the past 24 months from study start date or scheduled to undergo ACL reconstruction with a tissue graft augmented with BioBrace®.
  • Between 14 and 70 years old at the time of surgery.
  • Can understand the content of the subject information / Informed Consent Form (ICF) for the prospective portion of the study.
  • Is willing and able to participate in the prospective data collection protocol and comply with the required data collection.
  • If the subject has already undergone ACLR within the past 24 months, subject must have at least two (2) of the following measures at baseline and 1 year post-operatively:
  • International Knee Documentation Committee (IKDC)
  • Knee Injury and Osteoarthritis Outcome Score Junior (KOOS, JR.)
  • Patient-Reported Outcomes Measurement Information System (PROMIS-10)
  • Tegner Activity Scale (TAS)
  • Anterior Cruciate Ligament - Return to Sport After Injury (ACL-RSI)
  • Positive diagnostic imaging by MRI at baseline indicating an ACL tear

Exclusion criteria

  • Has other concurrent medical or other conditions (chronic or acute in nature) that in the opinion of the participating investigator may prevent participation or otherwise render subject ineligible for the study.
  • Is currently participating in an investigational therapy (device and/or pharmaceutical) within 30 days prior to entering the study or such treatment is planned during the 3 years following enrollment into the study.
  • Underwent or scheduled to undergo a multi-ligament reconstruction procedure (excluding cases where a torn MCL is treated non-operatively).
  • Females of child-bearing potential who are either pregnant or breastfeeding at the time of surgery.

Treatment and study plan

Anterior cruciate ligament reconstruction with BioBrace® augmentation

Device

An arthroscopic anterior cruciate ligament reconstruction (ACLR) will be performed and the tissue graft will be augmented with the BioBrace® Reinforced Implant. BioBrace® is intended for use in surgical procedures for reinforcement of soft tissue where weakness exists. It is a bioresorbable, biocomposite scaffold composed of a highly porous collagen sponge and reinforced with poly-L-lactic-acid (PLLA). When used in ACLRs, it is sutured alongside the tissue graft to augment and reinforce the graft construct. BioBrace® is designed to mechanically and biologically augment weakened or torn soft tissue and can be integrated into surgeons' standard of care ACL reconstruction techniques.

Arthroscopic anterior cruciate ligament reconstruction

Procedure

An arthroscopic anterior cruciate ligament reconstruction is performed using standard surgical procedure.

Primary outcomes

  1. Improvement in Function

    Time frame: 3 years post-op

    Improvement in function measured with International Knee Documentation Committee (IKDC) from baseline to 3 years post-surgery.

  2. Adverse Events

    Time frame: Baseline, 6-months, 1-, 2-, and 3-years post-op

    Evaluation of device-related adverse events

Secondary outcomes

  1. International Knee Documentation Committee (IKDC)

    Time frame: Baseline, 6 months, 1-, 2-years post-op

    Patient-reported functional and activity status as assessed by International Knee Documentation Committee (IKDC)

  2. Knee Injury and Osteoarthritis Outcome Score Junior (KOOS, JR.)

    Time frame: Baseline, 6 months, 1-, 2-, and 3-years post-op

    Patient-reported functional and activity status as assessed by the following: Knee Injury and Osteoarthritis Outcome Score Junior (KOOS, JR.)

  3. Patient-Reported Outcomes Measurement Information System (PROMIS-10)

    Time frame: Baseline, 6 months, 1-, 2-, and 3-years post-op

    Patient-reported functional and activity status as assessed by the following: Patient-Reported Outcomes Measurement Information System (PROMIS-10)

  4. Tegner Activity Scale (TAS)

    Time frame: Baseline, 6 months, 1-, 2-, and 3-years post-op

    Patient-reported functional and activity status as assessed by: Tegner Activity Scale (TAS).

  5. Anterior Cruciate Ligament - Return to Sport After Injury (ACL-RSI)

    Time frame: 6 months, 1-, 2-, and 3-years post-op

    Patient-reported functional and activity status as assessed by the following: Anterior Cruciate Ligament - Return to Sport After Injury (ACL-RSI)

  6. Secondary Surgical Intervention(s)

    Time frame: 6 months, 1-, 2-, and 3-years post-op

    The percentage of subjects who required additional surgical procedures following discharge from the BioBrace ACLR index procedure will be reported.

  7. Re-tear Rate

    Time frame: 6 months, 1-, 2-, and 3-years post-op

    Re-tear rate of the surgically reconstructed ACL tissue graft augmented with BioBrace. The percentage of subjects who experienced a re-tear of the augmented ACL tissue graft will be reported.

Study contacts

Contact information is provided by the study sponsor or research team.

Kelley Grynewicz

CONTACT

[email protected]

7274574955

Sponsors and collaborators

Lead sponsor

CONMED Corporation

Industry

Registry information

Official study title

Real World Evaluation of the Safety and Effectiveness of BioBrace® Augmentation in Anterior Cruciate Ligament (ACL) Reconstruction Procedures

Important dates

Study start
2025
Primary completion
2030
Study completion
2030
First posted
Apr 29, 2025
Registry last updated
Apr 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.